Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phio Pharmaceuticals (PHIO) Change in Accured Expenses (2016 - 2021)

Phio Pharmaceuticals' Change in Accured Expenses history spans 10 years, with the latest figure at $599000.0 for Q4 2021.

  • For Q4 2021, Change in Accured Expenses rose 2704.35% year-over-year to $599000.0; the TTM value through Dec 2021 reached $1.3 million, up 215.66%, while the annual FY2025 figure was $143000.0, 179.44% up from the prior year.
  • Change in Accured Expenses reached $599000.0 in Q4 2021 per PHIO's latest filing, up from -$49000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $652000.0 in Q2 2021 to a low of -$649000.0 in Q3 2018.
  • Average Change in Accured Expenses over 5 years is $51850.0, with a median of $95500.0 recorded in 2020.
  • Peak YoY movement for Change in Accured Expenses: plummeted 445.21% in 2018, then surged 2704.35% in 2021.
  • A 5-year view of Change in Accured Expenses shows it stood at -$147000.0 in 2017, then plummeted by 154.42% to -$374000.0 in 2018, then surged by 71.66% to -$106000.0 in 2019, then soared by 78.3% to -$23000.0 in 2020, then soared by 2704.35% to $599000.0 in 2021.
  • Per Business Quant, the three most recent readings for PHIO's Change in Accured Expenses are $599000.0 (Q4 2021), -$49000.0 (Q3 2021), and $652000.0 (Q2 2021).